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Short Peptides as Inhibitors of Amyloid Aggregation
Bradley Neddenriep, Anastasia Calciano, Daniel Conti, Erin Sauve, Marissa Paterson,
Edward Bruno and David A. Moffet*
Department of Chemistry and Biochemistry Loyola Marymount University 1 LMU Drive Los Angeles, CA 90045, USA
Abstract: The misfolding and aggregation of proteins into amyloid has been linked to a variety of age-related diseases.
Aggregation of proteins, such as A in Alzheimer’s disease and Islet Amyloid Polypeptide (IAPP, amylin) in type 2 diabetes, appears to lead to the formation of toxic assemblies. These assemblies range in size from small oligomers (2-8 proteins) to large fibrils (thousands of proteins). It remains unclear how these amyloidogenic proteins misfold and form toxic
species, but growing evidence suggests that inhibiting the aggregation of these proteins could slow, if not prevent altogether, the progression of these diseases. We describe the use of small peptides (<43 amino acids) as inhibitors of amyloid-based aggregation. These peptides, often short complementary segments of the amyloid proteins, can be useful (i) for
identifying the aggregation-prone regions of the amyloid proteins (ii) as models for drug discovery and (iii) as potential
therapeutic agents themselves.

Keywords:Amyloid Inhibition, Peptide Libraries, ABeta, Amylin, IAPP.
INTRODUCTION
Many proteins are known to adopt unwanted, misfolded
structures that can be linked to a variety of age-related diseases [1-3]. Proteins such as Islet Amyloid Polypeptide
(IAPP, amylin) in type 2 diabetes and A42 in Alzheimer’s
disease are known to misfold and aggregate into toxic oligomers and fibers. In these amyloid diseases, proteins misfold and self-assemble into a variety of structures. It remains
unknown if these misfolded proteins are the cause of their
respective diseases or a side-effect. However, evidence is
accumulating to suggest that the aggregation of amyloid proteins plays an important role in the development and progression of these diseases.
The amyloid diseases represent a serious threat to our
overall global health. Within the United States, the economic
and social costs associated with Alzheimer’s disease and
type 2 diabetes have been well documented over the past
decade. The Alzheimer’s Association estimates that 5.1 million Americans are currently afflicted with Alzheimer’s disease [4]. Likewise, the American Diabetes Association estimates that 23.6 million children and adults in the United
States have diabetes [5]. Because the prevalence of these
diseases increases with age, the number of people afflicted
with Alzheimer’s disease and type 2 diabetes will increase as
the population ages. If no treatments are found to slow these
diseases, it is estimated that 11 to 16 million Americans will
be afflicted with Alzheimer’s disease by 2050 [4] and as
many as 100 million Americans could have diabetes by that
time [6]. The economic costs of just these two amyloidogenic diseases is estimated to be more than $148 billion
annually for Alzheimer’s disease and $174 billion for type 2
diabetes.
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While the amyloidogenic proteins differ in many ways
(length, organismal localization, amino acid compositions),
they all form well-ordered fibrils and appear to be toxic to
living cells [7-14]. These similarities are not solely shared by
naturally occurring proteins, but have been identified in designed proteins expressed in mammalian cells [15]. These
results indicate that the formation of protein aggregates,
whether they are small oligomers or large fibrils, plays a
central role in cell toxicity and disease pathology. These
studies suggest that the mechanism of this cellular toxicity is
likely conserved from one amyloid protein to the next. These
results raise the hope that if a strategy is uncovered to prevent amyloid formation for one disease, the same strategy
may lead to therapies for many, if not all, of the remaining
amyloid diseases.
Many strategies are currently being assessed for preventing the formation of amyloid and toxic oligomers. Some
strategies rely on preventing the production of the amyloid
protein in the first place (for instance, inhibiting -secretase
activity in A production). Some strategies rely on removing
the amyloid protein after it has been produced (such as using
antibodies to remove A). Both of these strategies hold great
potential for slowing and/or preventing the onset of amyloidbased diseases. However, it remains to be determined if the
amyloid proteins themselves serve a useful purpose to the
organism. There may be a benefit to having the protein that
has not yet been determined. With this in mind, there have
been some recent successes made in slowing the rate of aggregation of amyloid proteins without having to remove the
protein entirely. Several classes of small molecules have
been identified as showing some activity toward inhibiting
the formation of amyloid. [16-27]. While small-molecule
aggregation inhibitors have been reported, none have been
developed into a clinically useful therapeutic.
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Since 2002, we have seen a considerable increase in the
number of reports identifying short peptides as inhibitors of
amyloid formation. While none of these peptides have been
developed into a therapeutic, the potential does exist. Unlike
small-molecule inhibitors of amyloid aggregation, short peptides can yield information regarding the amyloid aggregates
themselves. Many of the peptide inhibitors are truncated
versions of the full-length amyloid proteins. By identifying
the sequence regions that inhibit aggregation, we can infer
that those are the regions responsible for driving amyloid
aggregation. In this review, we will focus on the short peptide sequences comprised of naturally occurring amino acids
that have been identified for their ability to inhibit the aggregation of the amyloidogenic proteins A (Alzheimer’s disease) and IAPP (type 2 diabetes).
PEPTIDE INHIBITION OF ABETA AGGREGATION
Peptides showing an ability to inhibit the aggregation of
A can be organized into two major groups; rationally designed peptides (which are typically similar in sequence to
that of wild-type A) and randomly generated peptides
(those which are identified from peptide libraries that may,
or may not, show sequence similarity to wild-type A). The
advances made in molecular biology and biotechnology in
the past decade have made it possible to construct and screen
large peptide libraries to identify those sequences that interact with A. These library-screening experiments, which
were either impossible or impractical just a few years ago,
have successfully identified several amyloid inhibitors.
Rationally Designed
Aggregation

Peptide

Inhibitors

of

A

The earliest attempts to identify A aggregation inhibitors came from the sequence of A itself (Table 1). Many of
the first peptide inhibitors were designed to target the aggregation-prone hydrophobic core region of A. This region
Table 1.

Peptide Inhibitors of A42

Table 2.

Peptide Inhibitors of IAPP

(LVFFA) is considered by many to be the primary aggregation-prone site of A and is often termed the self-recognition
site [28-30]. Many rationally designed peptides retain the
LVFFA sequence, with the hope that the inhibitor peptide
will selectively bind to the analogous sequence of natural
A42 [28, 31-34]. What often differs among these peptides
are the N and C –terminal amino acids surrounding the
LVFFA core. These surrounding residues are thought to act
as aggregation blockers (termed -sheet breakers), preventing additional amyloid peptides from adhering to the Apeptide complex [35]. Many of these LVFFA peptides, and
their later-generation variants, have been shown to inhibit
A aggregation at stoichiometric concentrations and rescue
living cells from the toxic effects of A42. For example,
Garno and coworkers recently synthesized and studied 15
different variants having KLVFF as the core sequence (additional residues were added to the N-terminus and/or the Cterminus of this core sequence) [31]. From Thioflavin T and
transmission electron microscopy experiments, nearly all of
these peptides possessed some ability to inhibit aggregation
at a 1:1 molar ratio (40 μM peptide to 40 μM A40). Several
peptides inhibited aggregation by approximately 80% compared to samples lacking the inhibitory peptides. Atomic
force microscopy was used to identify the aggregation products of A40 alone, the peptides alone and A40 in the presence of the peptide inhibitors. Several peptides were found to
self-aggregate into spherical assemblies, yet still showed
inhibitory capacity. They found that placing positively
charged residues at the N-terminal end of the KLVFF sequence were less likely to inhibit than if positive amino acids
were placed at the C-terminal end. The authors also concluded that the peptides with the highest affinity to A40
showed the greatest ability to inhibit amyloid-based aggregation. These results seem to be typical of the KLVFF core
peptide inhibitors. These peptides demonstrate the potential
of rationally designed peptide inhibitors as amyloid blocking
agents.
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The hydrophobic core of A42 is not the only region
targeted for inhibition of aggregation. A42 aggregation has
been inhibited using C-terminal fragment (CTF) sequences
of various lengths [36-38]. The best of these inhibitors
spanned the final 13, 11 and 4 amino acids of A42 [38],
indicating that the length of the inhibitor peptide did not necessarily correlate with inhibitory propensity. Instead, the best
correlation between CTF and their physical properties appeared to rely on the ability of the CTF to form a coil-turn
conformation [38]. This conformation seems to appear in
other inhibitory models, such as the peptide hairpin inhibitor
of Teplow and coworkers [39]. While this peptide does contain one D-amino acid (D-Proline), the polypeptide is believed to form a hairpin turn held together by a disulfide
bridge.
The rationally designed peptides have proven to be a
strong class of inhibitory agents for A42. These peptides
continue to be modified with the ultimate goal to increase
their ability to inhibit amyloid aggregation. Many of these
peptides have been found to protect living cells from toxic
amyloid aggregates. Perhaps future iterations of these peptides will show even greater ability to protect cellular viability.
Peptide Inhibitors of A Aggregation Selected from
Combinatorial Libraries
Advances in molecular biology, coupled with the decreased cost of DNA synthesis, have led to a greater ability
to generate high-quality gene/protein libraries [40]. Libraries
that once took months to construct, can now be done in a
matter of weeks. While the ability to construct gene libraries
has greatly evolved over the past decade, the ability to select
for those variants that show a desirable activity has not.
There are very few techniques in the literature that describe
screens to select for peptides that inhibit amyloid aggregation and protect living cells from toxic protein aggregates.
Despite this paucity of screening techniques, those screens

(A)

(B)

that have been utilized have proven to be successful at identifying multiple amyloid-inhibiting peptides. We will discuss
each of these screening techniques and the inhibitory peptides they have identified.
Peptides Identified Using Phage-Display
Phage display has proven to be an excellent method for
screening large libraries of peptides to select for those that
bind to an epitope of interest [41]. Many of the libraries
screened by phage display have targeted large peptides/proteins. These libraries of larger peptides have generated sequences that inhibit A aggregation, but may prove
difficult to convert into a therapeutically useful drug. For
example, several papers have been published recently that
describe antibody-based, affibody, and other scaffold-based
proteins selected by phage display [42-52]. Many of these
selected proteins have been shown to inhibit aggregation, but
their therapeutic potential remains untested.
Kamijo and coworkers recently screened a randomized
heptapeptide library against A42 [53]. Their goal was to
identify peptides that could bind A42, but did not necessarily possess sequence similarities to A42. They identified
several peptides, rich in arginines, that showed in vitro ability to inhibit A42 aggregation. Size-exclusion chromatography and SDS-PAGE gel-shift assays indicated that several
of these selected peptides kept A42 from forming soluble
oligomers [53]. Additional experiments will need to be performed to assess how these peptides inhibit aggregation. Of
specific interest is why arginine-rich sequences were highly
selected in this screen.
Not all peptides identified with phage display have been
found to inhibit aggregation. Kiessling and coworkers identified several peptides that could bind to different aggregation
states of A40 [54]. While several peptides were identified
that could bind to A40, none slowed the rate of aggregation,
and many increased aggregation. Therapeutically, this increase in aggregation could be beneficial if, in fact, aggre-

Amyloid Peptide
Amyloid Peptide
Amyloid Peptide
Amyloid Peptide
Amyloid Peptide

Amyloid Peptide
Amyloid Peptide
Amyloid Peptide

Amyloid Peptide
Amyloid Peptide

Folded EGFP
Folded EGFP

41

Forms Amyloid

Self-assembly of
amyloid peptides
precludes EGFP folding
and fluorescing

Amyloid inhibitor prevents
self-assembly of peptides
and allows EGFP to fold
and fluoresce

(C)
Amyloid Inhibitor

Fig. (1). (A) Amyloidogenic peptides, such as A42 and IAPP self-assemble, ultimately leading to the formation of amyloid. (B) When
linked to an amyloid peptide, EGFP does not fold or fluoresce. The aggregation of the amyloid peptides prevents proper folding and fluorescence of EGFP. (C) Inhibitors that prevent the self-assembly of the amyloid peptides allow the EGFP to fold and fluoresce.
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Aβ42:
Library 1:

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
MSNKGGIIVLMVVVVVIADSHS
TTA AAAAA
NND DDDDD
SSG GGGGG

Aβ42:
Library 2:

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
MDKLVFFAEVVGSIADSHS
ALL AA
DII DD
GMM GG
VV

Fig. (2). Amino Acid Sequences of A42 and Library 1 and Library 2 Peptides. The amino acid sequence for A42 is shown. Library 1 was
constructed to have mixtures of amino acids in the bold-faced positions. Degenerate gene construction: Codon ANT encodes for an equal
mixture of I, T, N and S. Codon GNT encodes for an equal mixture of V, A, D and G. Codon NTN encodes for a mixture of F, L, I, M and V.
Table 3.

Oligos Used for the Construction of Gene Libraries 1 and 2

Library 1 Forward

5’-CTAGCTGT CAT ATG TCT AAC AAA GGC GCG ANT ANT GNT CTG ATG GNT GNT GNT GNT GNT ATT GCG GAT
AGT CAT AGT TAA-3’

Library 2 Forward

5’-CTAGCTGT CAT ATG CAG AAA CTG GNT DTN DTN GCG GAA GNT GNT GGC TCT AAC AAA TAA ATT GCG
GAT AGT CAT AGT TAA-3’

Reverse

5’- CGATAGGAC GAATTC CAG TGG TAG CTT GTG TGC CAA CAG TAG TTA ACG GTA GAA CCG TTA ACT ATG
ACT ATC CGC AAT -3’

Degenerate codons are underlined. Complementary regions are colored blue. All oligos are written from 5’-3’. N: equal mixture of A, T, G and C. D: Equal mixture of A, G and T.

gated A is less toxic than small oligomers. These aggregation-enhancing peptides may function to help sequester
A40 into less toxic fibrils rather than the more toxic soluble
oligomers.

fied three short peptides capable of inhibiting A42 aggregation [60]. We believe this screen can be used to select for
increasingly potent inhibitors of A42 by improving the selection conditions and the combinatorial library design.

Peptides Identified Using A42-EGFP

Gene libraries can be easily constructed using a variety of
techniques. Gene libraries can be designed to encode for
short peptides targeted to anneal to, and disrupt aggregation
of, the amyloidogenic A42 peptide. For example, Fig (2)
shows two peptide libraries targeted to mimic each of the
two hydrophobic regions of A42. Both gene libraries were
constructed using synthetic single-stranded oligos (Table 3)
and pieced together using oligo overlap and extension (Fig.
3). Gene variability was introduced to the gene libraries by
using degenerate codons encoding for combinatorial mixtures of amino acids (Table 3).

Hecht and coworkers described the use of a GFP-based
screen to assess the in vivo aggregation propensity of A42
in E. coli cells [29, 55]. This screen has been used to assess
the aggregation potential of A mutants [55-57] as well as to
screen for small molecules that can inhibit aggregation [58].
We recently used this screen, replacing GFP with enhanced
GFP (EGFP) to select for mutants of IAPP that resisted aggregation [59]. In this screen, the amyloid protein (such as
A42 or IAPP) is genetically fused to the reporter protein
EGFP. When expressed in E. coli, the Amyloid-EGFP fusion
proteins produce virtually no green color or fluorescence due
to the propensity of the amyloid proteins to aggregate (Fig.
1). However, when the amyloid proteins are prevented from
aggregating (either by mutagenesis or in the presence of an
aggregation inhibitor), the fused EGFP folds and fluoresces
brightly.
We have recently used this screen to select peptides from
different combinatorially randomized libraries for their ability to inhibit A42 aggregation [60]. Combinatorially diverse
library peptides were co-expressed in E. coli with the A42EGFP fusion protein. Peptides that prevented the aggregation
of the A42 allowed EGFP to fold and fluoresce. Individual
E. coli colonies expressing both a library peptide and amyloid-EGFP were screened to select for those colonies that
showed the greatest fluoresce. Using this screen, we identi-

Both peptide libraries were designed to mimic the hydrophobic patches of A42, with the intention of producing peptides that could anneal to the monomeric form of A42. Also
designed into the peptide libraries are strongly polar and
charged aspartic acid residues. These acidic residues are intended to incorporate a strongly charged “bump” on the library peptides that prevents the aggregation of additional
A42 proteins to an A42-library peptide complex. The library peptides are designed to act as two-sided patches; one



Library 1: 5’-CTAGCTGT CAT ATG TCT AAC AAA GGC GCG ANT ANT GNT
CTG ATG GNT GNT GNT GNT GNT ATT GCG GAT AGT CAT AGT TAA-3’,
Library 2: 5’-CTAGCTGT CAT ATG CAG AAA CTG GNT DTN DTN GCG GAA
GNT GNT GGC TCT AAC AAA TAA ATT GCG GAT AGT CAT AGT TAA-3’,
Reverse sequence for both libraries: 5’- CGATAGGAC GAATTC CAG TGG TAG
CTT GTG TGC CAA CAG TAG TTA ACG GTA GAA CCG TTA ACT ATG ACT
ATC CGC AAT -3’.
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side being sticky and annealing to monomeric A42, and the
other side presenting a repulsive residue (or residues) that
prevent additional A42 peptides from annealing.

is highly amyloidogenic, finding any substance to inhibit its
aggregation could be a potent weapon in the fight against
type 2 diabetes.

The gene library is cloned into one plasmid and cotransformed with the amyloid-EGFP plasmid into a suitable E.
coli expression host (Fig. 4). The resultant colonies are transferred to plates that can induce protein expression. With this
system, thousands of transformed colonies can be screened
to identify those few that show elevated levels of EGFP fluorescence.

It is well established that rodent IAPP (rIAPP) is
nonamyloidogenic and nontoxic. It is also established that
rats and mice are not known to develop type II diabetes [64],
strengthening the argument that inhibiting IAPP aggregation
could help to prevent type 2 diabetes. Rodent IAPP, which
differs from human IAPP by six amino acids, has been demonstrated to be capable of inhibiting human IAPP aggregation [65].

PEPTIDE INHIBITORS OF IAPP AGGREGATION

Five of the substitutions known to convert amyloidogenic
human IAPP into non-amyloidogenic rodent IAPP occur in
the 20-29 region of the peptide (Table 2). Because of these
substitutions the 20-29 region has long been described as the
amyloidogenic region of IAPP [32, 66, 67]. Recent studies
have indicated that several mutations outside of the 20-29
region can hinder fibrillogenesis, and are likely important for
aggregation [59, 68-74]. Several short peptides targeting this
aggregation-prone region have been identified [73]. Additionally, a single mutation in the middle of this aggregation
region, I26P, has been shown to act as a potent inhibitor of
IAPP aggregation [70].

In type II diabetes the amyloid-forming peptide is islet
amyloid polypeptide (IAPP, amylin). This 37 amino acid
polypeptide misfolds and forms toxic aggregates within the
pancreas. This misfolding into toxic aggregates, such as
small soluble oligomers or large fibers, is believed to contribute to the loss of pancreatic -cells. A great debate continues within the scientific community to identify the toxic
form (or forms) of IAPP. While the exact role of IAPP in
type II diabetes is unclear, it is known that IAPP is found as
extracellular deposits of amyloid in approximately 90% of
patients afflicted with type II diabetes [61-63]. This peptide

5’

3’
5’

3’
+ Klenow Polymerase
+ dNTPs

5’
3’

3’
5’

Fig. (3). Oligo overlap and extension: Single-stranded DNA oligos were designed having complementary 3’ overhang regions (dashed lines).
When mixed, the complementary regions anneal and act as templates for Klenow Fragment catalyzed DNA synthesis. Nucleotides not involved in annealing (solid lines) can be explicitly designed base by base or combinatorially varied.

Aß42-EGFP
pCDF-1b
Strep r

Library

+

pET21c
Ampr

1) Cotransformed into
BL21(DE3) E. coli
2) Plated on Nitrocellulose
on LB Plates

Strep and Amp Media

Move to IPTG
plate

IPTG, Strep, Amp Media

Fig. (4). Construction and selection of peptide libraries. Cotransformed cells were plated on nitrocellulose absorbed on LB plates containing
Ampicillin and Streptomycin. After incubation, resulting colonies are transferred to LB plates containing IPTG. Green-colored colonies are
selected and analyzed.
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Insulin is an additional peptide that is known to inhibit
IAPP aggregation [75]. Insulin is co-secreted with IAPP
from pancreatic B-cells. While the exact role these two peptides play in the development of type 2 diabetes remains to
be determined, it is not surprising that this metabolismdriving hormone is important in preventing IAPP aggregation. Raleigh and coworkers were able to determine the crystal structure of IAPP fused to maltose binding protein [76].
Based on the structure of IAPP in this fusion protein, they
were able to model the possible binding interaction between
IAPP and the B-chain of insulin, showing the importance of
IAPP Phe15 in this aggregation (Table 2 shows the sequence
of insulin as well as the residues of insulin suggested as interacting with IAPP).
In one of the few articles describing short peptide inhibitors of IAPP aggregation, Fraser and coworkers tested a series of hexapeptides, each overlapping with a segment of
IAPP [73]. When co-incubated with IAPP, several of the
peptides, such as GAILSST appeared to decrease the density
of fiber formation. More importantly, one peptide SNNFGA
(Table 2) had the ability to rescue cultured cells from IAPP
toxicity.

Neddenriep et al.
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[6]

[7]

[8]
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[10]

[11]

OUTLOOK
Over the past decade, we have witnessed a great increase
in the number of articles describing short peptides as inhibitors of amyloid aggregation. Advances in molecular biology
(which allows for the inexpensive synthesis of DNA libraries) and peptide synthesis (which have lowered the costs of
chemically synthesizing peptides) have made it possible to
both identify and synthesize specific peptides capable of
inhibiting aggregation. While it remains to be seen whether
short peptides can be used as therapeutic agents in preventing the amyloid diseases, these short peptide inhibitors can
aid in identifying the aggregation-prone regions of the amyloid proteins. These short peptide inhibitors can also be useful in identifying the important characteristics of potential
therapeutic agents in amyloid inhibition. Perhaps future iterations of peptides will be identified that can protect cells
from amyloid aggregates as well as resist our body’s natural
protein degradation machinery.
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ABBREVIATIONS
IAPP

=

Islet amyloid polypeptide

A

=

Amyloid -protein

EGFP

=

Enhanced green fluorescent protein.
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